NGNE
Neurogene Inc.
Next earnings Aug 10, 2026 (before open) · consensus $-1.46 EPS
Last earnings +2.1% on 2026-05-12
$32.03
▲ +5.33%$32.03▲ +80.35%
over 1Y
L $14.95EODHDH $34.37
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.3%
1W-0.7%
1M+19.2%
3M+57.4%
YTD+58.9%
1Y+80.3%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 15 analysts
Strong Buy
Conservative balance sheet (liabilities/equity 0.09x); but revenue fell -100.0% YoY.
Neurogene Inc. shows $0.00 in FY2025 revenue (-100.0% YoY), and -34.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $0.00 | $925K | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$60.7M | -$56.5M | -$55.6M | -$82.6M | -$103M |
| Net income | -$60.7M | -$55.2M | -$36.3M | -$75.1M | -$90.4M |
| Diluted EPS | -$1.10 | -$1.04 | — | -$4.28 | -$4.24 |
| Net margin | — | — | — | -8123.7% | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$395M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-18.1%
FCF yield-15.7%
Quality & risk
ROIC (est.)-30.8%
Free cash flow-$78.4M
Total debt—
Net cash$104M
Altman Z-Score10.79 safe
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+4.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4/APeriod ending 2024-01-162026-06-16open ↗4/APeriod ending 2024-06-142026-06-16open ↗4/APeriod ending 2025-06-122026-06-16open ↗3/APeriod ending 2023-12-182026-06-16open ↗8-KPeriod ending 2026-06-082026-06-08open ↗8-KPeriod ending 2026-06-032026-06-04open ↗8-KPeriod ending 2026-05-122026-05-12open ↗10-QPeriod ending 2026-03-312026-05-12open ↗4Period ending 2026-05-062026-05-08open ↗4Period ending 2026-05-052026-05-07open ↗144Filing2026-05-06open ↗3Period ending 2026-04-202026-04-20open ↗
Frequently asked
- Is Neurogene Inc. (NGNE) a buy?
- NGNE currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.09x); but revenue fell -100.0% YoY.
- What is Neurogene Inc.'s quality score?
- NGNE scores 36.179487179487175/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001404644, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 7:36:12 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.